(Total Views: 604)
Posted On: 08/15/2022 8:58:25 PM
Post# of 155869
page 7 scroll down slowly
One patient was administered leronlimab with stage 4 HER2+ breast cancer with metastasis to liver, lung, and brain. The patient received her first dose in November 2019 and remained on study drug until spring 2022
One patient was administered leronlimab with stage 4 HER2+ breast cancer with metastasis to liver, lung, and brain. The patient received her first dose in November 2019 and remained on study drug until spring 2022
(0)
(0)
